Benzoyl Peroxide

證據等級: L5

預測適應症: 4 個

Benzoyl Peroxide: From Acne Vulgaris to Acne Keloid

One-Sentence Summary

Benzoyl peroxide is a widely used topical keratolytic and antimicrobial agent, primarily indicated for the treatment of acne vulgaris. The TxGNN model predicts it may be effective for Acne Keloid (acne keloidalis nuchae), with 1 clinical trial and 2 publications currently providing indirect supporting evidence. Among the four predicted indications, acne keloid is the only one with a mechanistically plausible rationale and existing clinical evidence.

Quick Overview

Item	Content
Original Indication	Acne vulgaris (topical treatment)
Predicted New Indication	Acne Keloid (Acne Keloidalis Nuchae)
TxGNN Prediction Score	99.06%
Evidence Level	L4 (Preclinical / mechanism-based studies)
Malaysia Market Status	✓ Marketed
Number of Registrations	9
Recommended Decision	Proceed with Guardrails

All Predicted Indications Summary

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation
1	Vulvar inverted follicular keratosis	99.92%	L5	Hold
2	2-Hydroxyethyl methacrylate sensitization	99.43%	L5	Hold
3	Acrodermatitis chronica atrophicans	99.17%	L5	Hold
4	Acne keloid	99.06%	L4	Proceed with Guardrails

Note: Ranks 1–3 have no clinical trial or literature evidence and are classified as L5 (model prediction only) with “Hold” recommendations. The remainder of this report focuses on Acne Keloid (Rank 4), the only prediction with a viable mechanistic rationale and supporting evidence.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on well-established pharmacological knowledge, benzoyl peroxide (BPO) is an organic peroxide that acts through two primary mechanisms: (1) keratolytic activity — it promotes the shedding of the outer layer of skin, reducing follicular plugging; and (2) antimicrobial activity — it generates free radicals that oxidise bacterial proteins, particularly effective against Cutibacterium acnes (formerly Propionibacterium acnes), without inducing antibiotic resistance.

Acne keloidalis nuchae (AKN) is a chronic inflammatory condition of the hair follicles, most commonly affecting the occipital scalp and posterior neck. Its pathogenesis involves follicular occlusion, bacterial colonisation triggering inflammation, and subsequent aberrant fibrotic/keloidal scarring. The first two pathogenic steps — follicular plugging and bacterial-driven inflammation — overlap directly with the mechanisms BPO targets in acne vulgaris.

This mechanistic overlap makes the TxGNN prediction clinically plausible. In dermatological practice, BPO washes (5–10%) are already used off-label as adjunctive therapy in early-stage AKN management, typically combined with topical antibiotics or retinoids. The prediction therefore aligns with existing clinical experience, though BPO addresses only the inflammatory component and cannot reverse established keloidal scarring.

Why the Top 3 Predictions Are on Hold

Prediction	Reason for Hold
Vulvar inverted follicular keratosis	Benign follicular tumour treated by surgical excision. BPO’s keratolytic action cannot address neoplastic growth, and vulvar application carries mucosal irritation risk.
HEMA sensitization	Type IV hypersensitivity reaction requiring allergen avoidance and immunosuppression. BPO has no immunomodulatory properties and is itself a known contact sensitiser — could worsen the condition.
Acrodermatitis chronica atrophicans	Late-stage Lyme disease manifestation requiring systemic antibiotics (doxycycline/ceftriaxone). Topical BPO cannot reach deep dermal Borrelia organisms and has no known activity against spirochaetes.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07015931	Phase 1/2	Completed	23	Split-face comparison of 0.025% retinoic acid vs. 0.1% adapalene for mild acne vulgaris in Fitzpatrick III–V skin types. Not directly studying AKN or BPO, but relevant in that adapalene/BPO combination therapy is a standard regimen, and the trial population (darker skin types) overlaps with AKN-susceptible demographics. Small sample size limits extrapolation.

Relevance note: This trial is only indirectly related (Grade C). No clinical trials directly investigating benzoyl peroxide for acne keloidalis nuchae were identified. Further prospective studies specifically targeting AKN with BPO-containing regimens would be needed to advance the evidence level.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21034705	2010	Review	Actas Dermo-Sifiliográficas	Review of pseudofolliculitis barbae — a chronic inflammatory follicular condition sharing pathogenic features with AKN (follicular occlusion, inflammation, scarring in predisposed individuals). Discusses topical management strategies including keratolytics relevant to BPO use.
39090034	2024	Retrospective Review	Dermatology Online Journal	Retrospective review of 77 Black paediatric patients with acne vulgaris (2018–2023). Highlights that acne in skin of colour commonly leads to scarring, keloid formation, and post-inflammatory hyperpigmentation — directly linking acne pathology to keloidal outcomes and supporting the relevance of BPO-based regimens in this population.

Malaysia Market Information

Benzoyl peroxide is registered with 9 authorisations and has active market status in Malaysia. Specific product registration details (authorisation numbers, product names, dosage forms, and approved indications) were not available in the evidence pack at the time of data extraction.

To complete this section, detailed NPRA product listing data should be retrieved from the NPRA Product Search Portal.

Safety Considerations

Please refer to the package insert for safety information.

General safety profile of benzoyl peroxide (from established clinical knowledge):

Common adverse effects: Skin dryness, peeling, erythema, burning/stinging sensation at application site

Known sensitisation risk: BPO is a recognised contact allergen; patch testing may be advisable before extended use

Bleaching effect: Can bleach hair, fabrics, and clothing on contact

Concentration-dependent irritation: Higher concentrations (≥10%) associated with greater skin irritation

Detailed warnings, contraindications, and drug interaction data were not available in the evidence pack (Data Gaps DG001, DG002). Package insert consultation is essential before clinical decision-making.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Benzoyl peroxide’s keratolytic and antimicrobial mechanisms directly address the early pathogenic steps of acne keloidalis nuchae (follicular occlusion and bacterial-driven inflammation). While no dedicated RCTs exist for BPO in AKN, the drug is already used off-label in clinical practice for this condition, and the mechanistic rationale is sound. The prediction is limited by the absence of direct clinical trial evidence and BPO’s inability to address established fibrotic/keloidal changes.

To proceed, the following is needed:

Mechanism of action data (MOA): Retrieve complete pharmacological profile from DrugBank to formalise the mechanistic rationale
NPRA product registration details: Complete Malaysia market information with specific authorisation numbers and approved indications
Package insert safety data: Obtain full warnings, contraindications, and precautions from the Malaysian-registered product inserts
Clinical evidence gap-filling: Conduct a targeted literature search for case series or observational studies of BPO use in AKN (search terms: “benzoyl peroxide” AND “acne keloidalis” OR “folliculitis keloidalis”)
Formulation assessment: Confirm that available topical formulations (wash, gel, cream) and concentrations (2.5–10%) are appropriate for the posterior neck/occipital application site typical of AKN
Prospective study design: Consider a pilot open-label study of BPO wash (5%) as adjunctive therapy in early-stage AKN to generate Level 2–3 evidence

Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.